NeOnc's NEO100 Hits Phase 2a Primary Endpoint: 48.9% PFS-6 and 26-Month Median OS in Recurrent Glioma
NTHI sits 72% above its 52-week low of $3.005 on elevated volume (11× avg).
Summary
NeOnc Technologies reported positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, meeting its primary endpoint with a 48.9% six-month progression-free survival rate and a median overall survival of 26.09 months — roughly three to four times the historical benchmark. The company will seek FDA alignment on a registrational path.
Key Events · Product Development and Regulatory · NTHI
-
Primary Endpoint Met
The Phase 2a study of intranasal NEO100 met its primary endpoint with a six-month progression-free survival rate of 48.9% (95% CI 26.3–68.1) versus a pre-specified 20% benchmark for standard of care (p=0.0047).
-
Survival Signal Stands Out
Median overall survival was 26.09 months from recurrence, compared with a historical salvage benchmark of 6–9 months. At six months, 86.7% of patients were alive; 60.9% at 12 months; and 54.1% at 24 months.
-
Durable Disease Control
A 66.7% disease control rate was achieved (2 partial responses, 14 stable disease); five of 24 patients remain on treatment, with one progression-free for approximately 19 months and another in an ongoing partial response beyond 114 days.
-
Favorable Safety Profile
No major toxicities were reported; adverse events were predominantly low-grade, consistent with Phase 1 data. The intranasal, at-home administration supports chronic dosing.
Analysis · NTHI · Life Sciences
Intranasal NEO100 met its Phase 2a primary endpoint with a six-month progression-free survival rate of 48.9% versus a 20% historical benchmark, a statistically significant result (p=0.0047). Median overall survival reached 26.09 months from recurrence — roughly three to four times the 6–9 months expected with current salvage therapy. Five of 24 patients remain on treatment, with one progression-free for approximately 19 months and another in an ongoing partial response. The therapy was well tolerated with no major toxicities. These data, disclosed for the first time today, position NEO100 as a potential first-in-class targeted therapy for recurrent IDH1-mutant high-grade glioma, a setting with no approved options. The company plans to request a Type B meeting with the FDA to align on a registrational path, potentially via a single pivotal trial under accelerated approval. This is a thesis-altering clinical readout for a company that had only $2.0M in cash as of its last report and faces a going concern warning — positive data could unlock financing or partnership opportunities critical to its survival.
At the time of this filing, NTHI was trading at $5.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $112.8M. The 52-week trading range was $3.01 to $12.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.